Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Merger | Merged



About British Biotech

British Biotech is a diversified life-sciences company developing both drugs and research products. Merged with Vernalis PLC as part of an asset sale in July 2003.

British Biotech Headquarters Location

Watlington Road

Oxford, England, OX4 6LY,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest British Biotech News

Losses widen at British biotech Oxford Nanopore despite revenue jump

Mar 22, 2022

British biotech firm Oxford Nanopore Technologies saw its losses widen by £106m despite revenue increasing by nearly £20m in its first full-year results since becoming a public company. Oxford Nanopore – which sells portable and industrial-sized products to sequence DNA and RNA – attributed the losses to growth investments, share-based payouts and costs associated with its initial public offering (IPO). The company completed its IPO in October last year at a valuation of nearly £5bn. The listing was considered a win for London’s public markets, with British biotech firms often opting for the US to list. However, its market capitalisation has since slumped to £3.31bn. Oxford Nanopore saw revenue increase from £114m in 2020 to £134m in 2021. Despite gross profits increasing by 56%, rising costs in research and development, sales and administration ate into Oxford Nanopore’s net profits. The company also saw a significant decrease in revenue from Covid-19 testing as shrinking case numbers drastically lowered demand for the service. Revenues for Covid testing decreased from £48.3m in 2020 to just £6.7m last year. Oxford Nanopore chief executive Gordon Sanghera said: “We are proud of all that we achieved in 2021. We saw a significant increase in both existing and new research customers using our technology to address some of the world’s biggest problems, from cancer and human genomics to public health and environmental genomics.” Sanghera also pointed to a 29% “increase in scientific publications citing our technology”. He added that the company was looking at “potential uses for our technology in applied markets, from infectious disease to agricultural optimisation”. The company started as a spinout from the University of Oxford in 2005. Oxford Nanopore now has three UK offices, as well as three offices in the US. In addition, it has expanded into Asia with an office in China, Japan and Singapore. Shares in Oxford Nanopore were down by nearly 9% following the publication of its financial results.

  • When was British Biotech founded?

    British Biotech was founded in 1986.

  • Where is British Biotech's headquarters?

    British Biotech's headquarters is located at Watlington Road, Oxford.

  • What is British Biotech's latest funding round?

    British Biotech's latest funding round is Merger.

  • Who are the investors of British Biotech?

    Investors of British Biotech include Vernalis and Domain Associates.

  • Who are British Biotech's competitors?

    Competitors of British Biotech include Intas Pharmaceuticals, Rigel Pharmaceuticals, Creative Biomolecules, Cylene Pharmaceuticals, Renovis and 11 more.

You May Also Like

Choice Research of Birmingham

Choice Research of Birmingham is a company that manages clinical development trials.

Tolera Therapeutics

Tolera Therapeutics is developing targeted therapies for immune suppression and immune tolerance, designed for use in organ transplant surgeries and other medical settings requiring safer, more targeted immune modulation. The goal is to provide improved induction therapy with a better safety profile than current treatment options. The company's technology, which stems from organ transplant research done at the Cleveland Clinic, has been undergoing clinical research and has been tested in humans. The regulatory pathway is expected to bring a product to market in 2012.

Diasome Pharmaceuticals

Diasome Pharmaceuticals develops hepatocyte directed vesicle technology, an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes to improve disease management and quality of life. The company was founded in 2004 and is based in Cleveland, Ohio.

Kanisa Pharmaceuticals

Kanisa Pharmaceuticals is a pharmaceutical company focused on the acquisition, development and commercialization of therapeutics in the field of oncology.


Lifepharms is researching natural products for medicinal and agricultural uses, including anticancer and pox virus medications.


Metastatix is a pharmaceutical company based in Atlanta, GA. Founded in 2005, the company is developing and commercializing small- molecule drugs to treat severely debilitating or life-threatening diseases including cancer, HIV infection, and macular degeneration. Per the company, Metastatix has pioneered the development of a series of oral small-molecule CXCR4 inhibitors that have unprecedented biological activity in preclinical models. The company has licensed its technology from Emory University.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.